A recent study by Din et al. has demonstrated that a low dose of aspirin (75 mg per day) can decrease the incidence of colorectal cancer (CRC) after only 5 years of treatment. The study also shows that use of an NSAID before diagnosis of CRC does not improve survival.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial
Trials Open Access 20 September 2021
-
Protein kinase A antagonist inhibits β-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in ApcMin/+ mice
Molecular Cancer Open Access 15 December 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Din, F. V. et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 59, 1670–1679 (2010).
Dubé, C. et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann. Intern. Med. 146, 365–375 (2007).
Flossmann, E. & Rothwell, P. M. ; British Doctors Aspirin Trial and the UK–TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369, 1603–1613 (2007).
Baron, J. A. et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348, 891–899 (2003).
Cole, B. F. et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J. Natl Cancer Inst. 101, 256–266 (2009).
Arber, N. & Levin, B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 134, 1224–1237 (2008).
Gann, P. H., Manson, J. E., Glynn, R. J., Buring, J. E. & Hennekens, C. H. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J. Natl Cancer Inst. 85, 1220–1224 (1993).
Cook, N. R. et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294, 47–55 (2005).
Cuzick, J. et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 10, 501–507 (2009).
Johnson, C. C., Hayes, R. B., Schoen, R. E., Gunter, M. J. & Huang, W. Y. Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am. J. Gastroenterol. 105, 2646–2655 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Kraus, S., Arber, N. Do aspirin and other NSAIDs protect against colorectal cancer?. Nat Rev Gastroenterol Hepatol 8, 125–126 (2011). https://doi.org/10.1038/nrgastro.2010.217
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2010.217
This article is cited by
-
Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial
Trials (2021)
-
Protein kinase A antagonist inhibits β-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in ApcMin/+ mice
Molecular Cancer (2011)
